Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB018
- Development stage
- Phase 1
- Lead developer
- Polpharma Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PB018 is a biosimilar candidate of ocrelizumab (Ocrevus), a humanized monoclonal antibody targeting the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes. Developed by Polpharma Biologics, PB018 is designed to deplete CD20-positive B cells, which play a central role in the pathogenesis of multiple sclerosis (MS). By binding to CD20, the antibody triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). In September 2025, Polpharma Biologics licensed the commercialization rights for PB018 in the Middle East and North Africa (MENA) region to MS Pharma.
- Other names
- ocrelizumab biosimilar
02
Targets
Beyond the preview
Go deeper on PB018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB018.